Squamous cell carcinoma of the vulva is predominantly a disease of the elderly, where the mainstay of treatment is radical surgery. Local vulval recurrence (LVR) is a significant problem for these patients, and the rates of recurrence have not improved over the last three decades. Disappointingly, we still lack an understanding of how LVRs develop, and the best approach to prevent and manage the condition. This review discusses recent insights into the key prognostic factors that influence the risk of recurrence, focusing on the role of tumour-adjacent non-neoplastic epithelial disorders, which are thought to play a causative role.
Introduction
Vulval cancer comprises only 6% of all gynaecological malignancies reported in the UK, with squamous cell carcinoma (VSCC) making up 90% of all cases. It is predominantly a disease of the elderly, with three-quarters of cases affecting those aged over 60 years. 1 Radical vulvectomy is the mainstay of treatment for VSCC, with the extent of surgery depending on a number of factors that include: the size of the tumour; its location and proximity to vital organs; fitness to tolerate major surgery; FIGO stage; and wishes of the patient. Recurrent disease is common following primary treatment in VSCC, with more than half of the cases recurring locally within the vulvoperineal area. 2, 3 The rate of local vulval recurrence (LVR) has not changed over time and affects at least one in four patients following primary treatment, as reported in previous studies (Table 1) . 2, 4 Inadequate surgical excision has always been thought to be the main reason attributed to the development of LVR, but this belief is increasingly being challenged by new evidence. 5, 6 Furthermore, a number of studies have shown that other clinicopathological factors are equally important in determining the timing, pattern, and frequency of LVR following surgery: in particular, the presence of non-neoplastic but dysplastic epithelium found adjacent to the primary tumour. [7] [8] [9] [10] The latter is of particular interest given that more than two-thirds of VSCC cases arise in a background of histologically abnormal or dysplastic epithelium, such as vulval intraepithelial neoplasia (VIN) or lichen sclerosus (LS). 11 Managing LVR can be challenging, especially in the elderly population, who often have other medical comorbidities, and in those who have previously received extensive surgery or exposure to radiotherapy. Further surgery is often associated with physical and psychosexual comorbidities and, in some instances, can result in the loss of urinary and bowel functions. Disappointingly, we still lack an understanding of how LVRs develop, and the best approach to prevent and manage the condition. This review discusses recent insights into the key prognostic factors that influence the risk of LVR and focuses on the role of non-neoplastic epithelial disorders (NNEDs), which are thought to arise from a field of molecularly altered epithelium, termed a 'field of cancerisation'.
The dual pathobiology of VSCC
Like squamous cell carcinoma of the head and neck (HNSCC), VSCC is known to arise through human papillomavirus (HPV) -dependent and -independent routes (see Figure 1) . The current disease paradigm holds that following persistent infection with high-risk (HR) HPV strains, women are at risk of developing usual or classical vulvar intraepithelial neoplasia (uVIN), which subsequently progress into basaloid or warty-type squamous cell carcinoma (SCC). 12, 13 It is estimated that 40% of all VSCC cases arise through the viral-dependent route; interestingly, the prevalence of HR-HPV-positive tumours is 20% higher in the USA compared with the UK. [14] [15] [16] [17] [18] [19] Most cases of the tumour test positive for HPV16 and, to a lesser extent, HPV18 and HPV33. 20 HPV-associated tumours typically affect younger women, aged <65 years, and the incidence in this age group is reportedly increasing in the UK and elsewhere. 1 This increase is a reflection of the rising incidence of the precursor lesion, uVIN, in young women, caused in part, by the rise in the prevalence of infection with HR-HPV strains. 20 Although women with uVIN often suffer debilitating physical and psychosexual symptoms, the risk of progression to VSCC is substantially lower than that of cervical intraepithelial neoplasia; current estimates of disease progression are less than 10%. 21 The virus-independent route is associated with the development of keratinising tumours in a background of differentiated intraepithelial neoplasia (dVIN) or LS. 12, 13 It is thought that the primary trigger of carcinogenesis in this setting is chronic inflammation, which results in repeated injury, scarring, and ultimately sclerosis of the affected epithelium. The sustained episodes of cell renewal and repair, which accompanies chronic inflammation, are associated with DNA damage and a high probability of mutation or silencing of tumour suppressor genes (TSGs), which, over time, can result in oncogenic transformation. 22 Nevertheless, it remains unclear whether LS gives rise to dVIN, as there is no clear-cut connection between the two conditions. Similarly, it is also unclear whether dVIN, like uVIN, is a precursor lesion in HPV-negative VSCC. Women within this age group are usually older (>65 years), and critically they are also more likely to have other medical comorbidities, which may pose particular challenges in managing their cancer.
Although the current theory suggests that VSCC may arise through these two distinct pathways, our recent study has shown that resected tumour specimens from almost a third of patients were found to have LS, uVIN and dVIN co-existing with each other. 7 This finding raises the question as to whether the two routes to the development of VSCC are mutually exclusive. Understanding the underlying pathobiology that leads to the development of VSCC is crucial, as many studies have found that the presence of NNEDs found adjacent to the primary tumour appears to influence the rate and pattern of local recurrence. [7] [8] [9] [10] 23, 24 Furthermore, in other HPV-associated cancers, such as HNSCC and anal cancer, there is compelling evidence to suggest that HPV-positivity confers a survival advantage. Despite this clear-cut correlation in these two diseases, however, studies on VSCC have failed to demonstrate that HR-HPV positivity is an independent predictor of diseasefree survival. 19, [25] [26] [27] The difficulty in revealing the expected association with HPV status in women with VSCC may flow in part from the frequency with which uVIN co-exists alongside LS and dVIN, both of which impose an increased risk for the development of LVR. 7 It is also worth noting that the detection of HR-HPV DNA in tumour specimens does not necessarily indicate the presence of transcriptionally active virus, given that the virus might have undergone integration, and become methylated and transcriptionally silent. 28 Alternatively, the presence of HR-HPV DNA might constitute a transient reactivation or new infection that is not necessarily related to viral-driven oncogenesis. 29 With the complexity of the HPV life cycle, the significance of HR-HPV DNA positivity in VSCC remains unclear. Further studies are required to measure the levels of expression of the HR-HPV oncogenes and its surrogate markers (E7, p16
INK4a
, and MCM7): these biomarkers would confirm whether oncogenesis is driven through the HR-HPV route. Figure 1 . VSCC can be derived from the HPV-dependent (red) and HPV-independent (blue) routes. Persistent HR-HPV infection gives rise to uVIN, which subsequently develops into basoloid or warty VSCC, if left untreated. Keratinising VSCC is usually found arising in the background of LS and dVIN. It remains unclear whether dVIN is a precursor lesion for LS, and whether LS can give rise directly to VSCC, as there is no stepwise histological model of carcinogenesis in the setting of chronic LS (blue dotted lines).
Topography of VSCC recurrence
Like HNSCC, our recently published study, along with two others, has identified two different patterns of local recurrence in VSCC (Figure 2) . A local vulval recurrence can occur on a site previously occupied by, or distant to, the primary tumour. 7, 8, 23 This pattern of local recurrence was first described in SCC of the oral cavity and upper respiratory tract, 30 and, like VSCC, the former can be derived from both HPV-dependent and HPV-independent routes. Molecular profiling of HNSCC has identified three distinctive patterns of local recurrence. Tumours that arise on a site previously occupied by the primary tumour are termed a local relapse (LR), and are thought to be a true local recurrence, whereas tumours that occur at least 2 cm or more away from the primary tumour are termed second field tumours (SFTs) or second primary tumours (SPTs), and are thought to constitute new tumours that could be genetically related (SFTs) or unrelated (SPTs) to the primary tumour. 31 Although still speculative, it is thought that both SFTs and SPTs arise within an area of genetically altered pre-neoplastic epithelium contiguous with the primary tumour that has a propensity to undergo malignant transformation. 32 Unlike HNSCC, a detailed examination of the topography of local recurrences in vulval cancer has not been adequately described. As such, very few retrospective cohort studies have attempted to categorise LVR based on the site and time at which the disease recurs following primary surgery. Bosquet et al. defined 'recurrence' as a disease that relapses within 5 years of treatment, whereas those that relapse after 5 years were termed a 're-occurrence'. 33 Both Regauer et al. and Oonk et al. postulated that disease recurring locally within 3 months of treatment is primarily the result of treatment failure, whereas van der Velden et al. described 'true' local recurrence as disease recurring within 2 cm of or 'near to' the excision scar. 9, 34, 35 It is important to note, however, that the definitions of local recurrence used by these authors are purely hypothetical and based on observational studies and, unlike the case for HNSCC, were not based on molecular profiling.
Clinicopathological determinants of LVR
Tumour-free pathological margins of 8 mm or more, measured after formalin fixation, is considered to be the gold standard practice to minimise local disease recurrence. The current surgical practice advocates the removal of at least 15 mm of disease-free tissue, lateral and deep margins, so that after fixation histological cancer-free margins of ≥8 mm can be achieved to avoid LVR. 36 This recommendation is based on a study conducted by Heap et al. on a small retrospective cohort. 37 The study found that none of the patients with pathological margins of ≥8 mm had recurrent disease, and local recurrence was only found in those with pathological margins of <8 mm. Although a number of independent studies support these findings, 23, 38 other more recent studies, which interrogated pathological margins in addition to other clinicopathological determinants, dispute the notion that an inadequate excision margin is the sole reason that contributes to LVR. [5] [6] [7] After an extensive review of the literature, we have identified 27 independent retrospective cohort studies that have assessed the clinicopathological factors that determine LVR (Table 1) . Collectively, these studies found that in addition to inadequate excision margins there were other clinical determinants that influenced the risk of LVR. These included: groin node metastasis; the presence of LS and VIN (usual and differentiated type VIN) adjacent to the primary tumour; older age group; tumour size; tumour multifocality; histology grade; lymphovascular invasion (LVSI); perineural invasion; site of tumour; the type of surgery performed; and others. [4] [5] [6] [7] 9, 11, 23, 33, 34, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] It remains unclear, however, which of the risk factors best predict LVR, as each study identified different predictors, and none were in total agreement with each other.
The inconsistencies in the findings from each retrospective study can be attributed to a number of possibilities. Firstly, different methodologies were used in each study to collect and analyse its results; secondly, the majority of these studies were conducted in a single institution where clinical practice in managing VSCC can be substantially different; thirdly, there was a lack of consistency in the clinical determinants used in each study; fourthly, the definition for LVR varies between each study and, at times, is used interchangeably with distant metastasis; and lastly, there was a lack of consensus in defining what constituted a true LVR. As a result, these studies failed to identify the common prognostic variable(s) involved in LVR. Taking into account the limitations of these studies, we conducted an analysis of our cohort to evaluate all potential clinicopathological determinants previously implicated in the development of LVR. 7 We also dichotomised local recurrences into LR or SFT/SPT, according to the definitions obtained from molecular studies on HNSCC. Interestingly, our results showed that more than half of the cases of local recurrence occurred at a site distant to the primary tumour; we also found that the presence of LS appeared to be the only clinical determinant that reliably predicts LVR. These patients were not at greater risk of developing distant metastasis when compared with other clinical determinants evaluated, suggesting that local disease recurrence probably occurs as a result of the continued chronic inflammatory dermatosis associated with the residual LS. Although we have yet to perform molecular profiling of the tumour specimens obtained in our study, we believe that LVR (both SFTs and SPTs) originate from a 'field' of molecularly altered epithelium that has acquired the necessary genetic changes to undergo malignant change. Contrary to previous beliefs, they do not occur as a result of inadequate excision margins, as described by Heap and colleagues. It is also worth highlighting that Heap et al. drew their inferences solely from unadjusted estimates, and their findings could be confounded by other clinicopathological variables not evaluated in their study.
Field cancerisation and LVR
The concept of field cancerisation was first proposed by Slaughter et al. in 1953 , who studied the histology of dysplastic epithelial tissue at tumour-adjacent surgical margins in an attempt to explain the reason for the development of multiple primary tumours and local recurrence in the oral cavity and upper respiratory tract. 30 In the original study, histological examinations were performed on normal tissue at surgical margins adjacent to the tumour. This study revealed the presence of multiple independent primary lesions and evidence of hyperplastic or atypical epithelium in seemingly histologically normal tissue contiguous with the primary tumour. Since the development of molecular biology, the concept of field cancerisation has now been redefined in molecular terms. Mutation or epigenetic silencing of growth-promoting or tumour-suppressor genes predisposes epithelium to undergo oncogenic transformation, allowing genetically altered cells to expand and colonise large areas of the epithelium. This phenomenon partly explains the multifocality of tumours, as secondary tumours or local recurrences, such as SFTs and SPTs, emerge some years later after removal of the primary tumour. The multifocality and multicentricity of vulval neoplasia, with its propensity to recur locally but at sites distant from the primary disease, point to this tumour arising within a field of cancerisation in which at least some of the molecular abnormalities present in the primary tumour will be detected in adjacent histologically normal epithelium.
As more than two-thirds of VSCCs arise on a background of atypical skin, in the form of uVIN, dVIN, or LS, 11 it is plausible that these non-neoplastic epithelial disorders arise from molecularly altered epithelium that is generated through virus-dependent and -independent routes. As such, NNEDs may constitute pathological biomarkers that indicate the presence of a molecularly altered field of epithelium. In the case of uVIN, these lesions are derived from HR-HPV-infected epithelium that has acquired additional molecular changes that have progressed to high-grade VIN. Several studies performed on women infected with HIV revealed the presence of multifocal HPV-associated warts and uVIN lesions/condylomata in the genital tract, pointing to the existence of a cancer field in these patients. 53, 54 Using molecular analyses involving X chromosome inactivation, Rosenthal and colleagues revealed that high-grade VIN lesions contiguous with VSCC were of clonal origin, raising the possibility that these VSCCs were derived from molecularly altered clones within the VIN lesions. 55 However, the question of whether HR-HPV infection per se generates a cancer field is currently unclear. Although data for VSCC is unavailable, a recent study performed in HNSCC has revealed that normal epithelium obtained from resection margins were uniformly HPV negative, suggesting that at least in this disease HR-HPV may not generate a field of molecularly altered epithelium. This finding supports the notion that unlike HPV-negative HNSCC, HR-HPV-positive HNSCC exhibits lower rates of local recurrence. 56 Although uVIN is a putative precursor lesion for HPVpositive VSCC, it is still debatable whether LS is a precursor lesion for the HPV-negative counterpart. Although recent evidence shows that residual LS that remains after excision of the primary tumour increases the risk of local recurrence, 7-9 the absolute risk of recurrence in these women is not well defined. The notion that LS generates a field of cancerisation, much like that observed in HPV-negative HNSCC, is a strong but as yet unproven concept; however, such an idea is not without foundation. It is now well established that chronic inflammation, coupled with sustained episodes of wound-healing, can predispose epithelial tissue to oncogenic transformation. 57 It is still unclear whether inflammation plays a permissive or promoting function in the generation or expanding of 'initiated' (i.e. mutated) cells. Chronic inflammation is associated with abnormal cytokine and growth-factor production, which can fuel the expansion of molecularly altered or premalignant cells. A number of studies have shown that LS lesions overexpress p53 protein and, in a significant proportion of cases, harbour mutated TP53 genes. 22, 58, 59 The induction of p53 is most likely associated with a DNA damage response, induced through the production of reactive oxygen species (ROS) or by ischaemic stress, both of which are produced during chronic inflammation. Increased levels of ROS are associated with the recruitment of the epigenetic modulator, DNMT1, to CpG-rich islands upstream of promoters of both growth regulatory (i.e. p16
INK4A
) and genes involved in the DNA damage response. 60 Chronic or sustained bouts of inflammation also cause alterations to the underlying stroma, converting normal fibroblasts into myofibroblasts, which produce cytokines, chemokines, and growth factors that can promote the growth of pre-malignant epithelial cells. An overwhelming body of evidence now supports a key role of the stromal microenvironment in field cancerisation and the development of both primary tumours and local recurrences. 60 This is particularly relevant as previous clinical studies that evaluated the risk of LVR following an en bloc vulvectomy, and a triple incision, showed no difference in risk, despite the removal of less 'normal' tissue in the latter procedure. [61] [62] [63] [64] Therefore, removing excessive non-neoplastic skin during primary surgery may not have prevented the development of LVR, as the adjacent skin brought together to close the wound may have already undergone a 'field transformation' that may eventually give rise to an LVR.
The challenges in managing local VSCC recurrence and future therapies
The treatments for LVR have not changed over the last three decades, and surgical excision continues to be the only treatment modality for cure. 2, 65 Surgery, however, may not be suitable for all patients, and the procedures can be challenging, especially in those who have previously had wide radical excision or radiotherapy. Reconstructive surgery is often required following primary excision to restore anatomy and function, as extensive scarring from previous surgery often reduces tissue volume and renders its flexibility to achieve primary closure. As a result, a skin flap is often harvested to cover the defect left after radical surgery. For a tumour that recurs and encroaches the urethra, anus, or vagina, pelvic exenteration followed by reconstructive surgery may be required to remove the disease completely, if the patient is physically fit enough to undergo the operation. For patients who previously had radiotherapy to their vulval area, wound breakdown following subsequent surgery is common because irradiated skin often has an inadequate blood supply and a slow healing rate, making skin grafting unsuitable for most of these women.
Squamous cell carcinomas, in general, are radiosensitive, but several studies have revealed poor treatment responses for large tumours when radiotherapy is used alone without surgery; 2 however, radiotherapy alone has been used successfully to treat low-volume disease that recurs in the vulva. 66 The use of concurrent chemotherapeutic agents, such as 5-flurouracil, Mitomycin C, and platinum agents, with irradiation has proven effective in managing largevolume disease in patients who have not had radiotherapy or in those who are physically unfit for surgery. 67 Neoadjuvant chemoradiotherapy followed by surgery is still superior to chemoradiotherapy alone in treating local recurrences, as overall survival is significantly better in those who can have surgery. 67 Concurrent chemoradiotherapy may also be used to reduce the tumour volume before surgery, sparing patients who required exenterative surgery from having a simple radical excision, but defunctioning colostomy may be necessary in cases where the tumour recurs in close proximity to the anorectal canal.
2 Nevertheless, as VSCC mostly affects the elderly population, only a small number of patients are physically fit enough to endure such forms of aggressive triple therapies that involve chemoradiation and surgery. As currently chemotherapeutic agents are used as an adjunct to radiotherapy or surgery, and in palliative setting, there is a need to look for new chemotherapeutic drugs that can be used as a lone therapy for VSCC so that we are less reliant on surgery.
Thus far, the chemotherapeutic regimes for VSCC are based on those used in other gynaecological malignancies, particularly cervical cancer; however, given the similar pathogenic routes displayed by VSCC and HNSCC, where tumours arise through HPV-dependent or independent routes, coupled with local disease recurrence arising within a field of cancerisation, we believe that future therapies for VSCC should be modelled on those developed for HNSCC. Until recently, current therapeutic options for the treatment of HNSCC have been limited to standard cytotoxic chemotherapies, used alone, or in combination with the EGFR-targeted antibody, Cetuximab. 68 In recent years, several immune-based therapies have been developed that have shown significant promise in the management of locally advanced and recurrent HNSCC. 69, 70 The most notable of these therapies involve the use of immune checkpoint inhibitors, which have been shown to be effective in several phase I-III clinical trials. One such drug, Pemprolizumab, [71] [72] [73] which targets the programmed cell death protein-1 (PD-1) on tumour-infiltrating lymphocytes (TILs), has been licensed by the US Food and Drug Administration (FDA) for the treatment of locally advanced and recurrent HNSCC. By blocking inhibitory molecules or, alternatively, activating stimulatory molecules, these immunomodulatory therapies are designed to enhance or unmask pre-existing immune responses to tumour cells. Several clinical studies have shown improved patient outcome when such immune checkpoint inhibitors are used alone or in combination with conventional chemotherapies or Cetuximab. 74, 75 Other approaches have focused on the development of cancer vaccines, which are designed to elicit an immune response against tumour-specific or tumour-associated antigens, encouraging the immune system to attack cancer cells bearing these antigens. Such an approach may have utility in HPV-positive VSCC, where tumour cells express the HPV-encoded E6 and E7 proteins. Clinical trials are being undertaken to evaluate such a strategy in HPV-positive HNSCC.
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Conclusion
Currently, there is a paucity of knowledge regarding the timing, topography, and aetiology of local VSCC recurrence. The notion that inadequate surgical excision margins are the driver for local recurrence is increasingly being challenged by studies using more sophisticated statistical analysis to evaluate the clinical determinants that predict LVR. Based on current evidence, we hypothesise that LVR arises within a field of molecularly altered epithelium that is generated as a result of chronic inflammation or infection with oncogenic HPV strains. We suggest that LVRs develop in a pre-existing field of molecularly altered epithelium from clones that have acquired the necessary mutations to undergo malignant transformation. Future studies should use molecular profiling techniques to identify the molecular changes present in these pre-cancerous fields so that potential biomarkers or gene signatures can be determined, and these used to stratify patients into those who are most likely at risk of developing local recurrences. Unlike HNSCC, the contiguous nature and ease of accessibility of the vulva made this organ an ideal model to study how the field of cancerisation develops, and the key molecular changes that predispose cells within the field to tumour formation. This analysis would allow us to develop field therapies that could be administered in the short-or long-term to delay or prevent local VSCC recurrence. In the case of LS-associated VSCC, where chronic inflammation appears to play a vital role in disease pathology and tumour recurrence, the use of topical steroids, an immunosuppressant, may prevent or delay local recurrences by reducing inflammation and re-establishing a more 'normal' stromal microenvironment.
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